SHC (Sotera Health Co) Risk Assessment


SHC Sotera Health Co SHC
74 GF Score
Price $17.86
GF Value $16.34
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Sotera Health Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Sotera Health Co is: High Risk: High uncertainty with risk-return tradeoff.

Sotera Health Co  (NAS:SHC) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Sotera Health Co Risk Assessment Related Terms

SHC vs VCYT, RDNT, BLLN: Risk Assessment Comparison

For the Diagnostics & Research subindustry, Sotera Health Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sotera Health Co Risk Assessment vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Sotera Health Co's Risk Assessment falls into.


SHC
74GF Score
Sotera Health Co SHC
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sotera Health Co (SHC) Overvalued in 2026?

Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued. The current stock price of $17.86 is trading 9.3% above its estimated GF Value™ of $16.34. GuruFocus considers Sotera Health Co to be Fairly Valued.

Key valuation signals for SHC:

  • Risk Assessment:
  • GF Value™: $16.34 vs. price of $17.86 (9.3% above fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sotera Health Co Business Description

Address 9100 South Hills Boulevard, Suite 300, Broadview Heights, OH, USA, 44147
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
74GF Score

Get the complete analysis for SHC

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.86
Price
$16.34
GF Value